$BOLT News

Bolt Biotherapeutics, Inc. (BOLT) M&A Call Prepared Remarks Transcript

Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications

Bolt’s Acquisition Positions It To Advance Prana’s Inspire Multispecific Antibody Pipeline; Phase 2 PRA-216 Readouts Expected Starting Q2 2027

Bolt Biotherapeutics Secures $120M Private Placement, With Potential Additional $60M From Warrant Exercise To Fund Operations Into 2028

Bolt Biotherapeutics Acquires Prana Therapies In Sign-And-Close Reverse Merger, Shifts Focus To Multispecific Antibody Pipeline; Prana Holders to Own 51.7% of Combined Company, Backed by Up To $180M Financing

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics Q2 EPS $(4.57) Misses $(2.88) Estimate, Sales $5.000K Miss $500.000K Estimate

Bolt Metals Announces Closing of Option to Acquire the High-Grade Floralia Iron Project

Rodman & Renshaw Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $22

HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target

Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics Q1 EPS $(4.31) Misses $(2.85) Estimate, Sales $26.000K Miss $1.500M Estimate

Bolt Metals Corp. Announces Appointment of Chief Financial Officer and Corporate Secretary

HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target

Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics Q4 EPS $(3.84) Beats $(4.30) Estimate, Sales $2.500M Beat $666.667K Estimate

Bolt Biotherapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS (FOR THE TREATMENT OF CANCER)".

Bolt Biotherapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.